- Email: [email protected]
OSMONICS TO INVEST IN NEW RO FACILITY
FIAJULY.qxd
6/24/02
1:58 PM
Page 16
Filtration Industry Analyst
NEWS
CLARCOR ACQUIRES UK FILTER MAKER Clarcor Inc has acquired for around US$6.5 million Warrington-based Locker Filtration Ltd, a UK manufacturer of heavy-duty air filters, diesel and gas turbine air intake system filters and specialty filter products. The acquisition of Locker, with annual sales of around US$14.0 million, provides Clarcor with an air filter manufacturing facility in Europe, and will allow the company to provide its European sales organizations with an additional filter supply source. Currently, most of the air filter products sold by Clarcor into the European market are exported from the company’s North American plants. Norm Johnson, Clarcor’s chairman and CEO, said, “By transferring additional production into the Locker plant, we will be able to increase the utilization of its manufacturing capacity and improve the profitability of our European sales. In addition to lowering our European product acquisition costs, we will free up needed capacity in our North American manufacturing plants.”
H2O INNOVATION PURCHASES BIOTREATMENT COMPANIES H2O Innovation (2000) Inc has acquired the common and preferred shares of OxydH2O Canada Inc, Bioflo Inc and 3765415 Canada Inc (OxydH2O/Bioflo) for C$1.13 million. OxydH2O/Bioflo designs and manufactures turnkey systems for biological treatments using fixed film growths, such as the rotating biological reactor (RBR) and the textile Bioreactor Bio-Fosse, which uses a synthetic matrix as a biological support.
16
July 2002
“This acquisition is a tremendous business development opportunity for both organizations. The combination of our operations and technological know-how will immediately increase our sales and enhance the development of new market networks, since OxydH2O/Bioflo has representations in North Africa, Latin America, the Philippines and Canada,” said Guy Goulet, president and CEO of H2O Innovation. The purchase will extend H2O Innovation’s product line to include two products certified as standard by the Ministère de l’Environnement du Québec and the Ministère des Affaires Municipales et de la Métropole du Québec for wastewater treatment. It will also allow H2O Innovation to maximize production resources at its Ham-Nord plant in Quebec, and, says the company, to improve gross margins and break even more quickly. The C$1.13 million purchase price includes a cash payment of C$159 094, and C$289 105 payable by the issuance of 963 685 H2O Innovation common shares at the transaction’s closing date. Jean-Jacques Demers and Lise Nantel will continue to head OxydH2O/Bioflo.
OSMONICS TO INVEST IN NEW RO FACILITY Osmonics Inc is to build a dedicated, state-of-the-art reverse osmosis (RO) membrane and spiral-wound element factory in response to increased demand for its RO treatment technologies. The new factory will encompass a 60 000 square foot expansion of Osmonics’ existing Minnetonka headquarters and manufacturing facility, and increase the total size of the site by almost 20%. The new facility, complete with new manufacturing equipment,
is expected to be fully operational in 2004. “In addition to meeting future market demand, the expansion will allow us to incorporate new, more efficient manufacturing processes and equipment to streamline how we produce these high-volume products, resulting in faster time-to-market for our customers and higher returns for Osmonics,” said Dean Spatz, Osmonics’ CEO. The focused manufacturing plant will produce RO, nanofiltration and ultrafiltration membranes and elements for water purification applications. The extra space will also allow for expansion of current cartridge filtration production in the existing Minnetonka facility. Osmonics’ Filtration and Separations Group, which represents 40% of Osmonics’ total revenue, will be responsible for managing the extension project and eventual full-scale production.
VIVENDI PLANS WATER SELL-OFF Vivendi Universal’s board of directors and Vivendi Environnement’s supervisory board have approved a plan to raise up to 2 billion by reducing Vivendi Universal’s stake in Vivendi Environnement to just over 40% from around 63%. The move follows intense speculation that such a sale was likely, as the company continues making efforts to reduce its heavy debt load. The transaction will be completed when market conditions are appropriate and as soon as practicable. Vivendi Universal will sell around 15% of its shares in Vivendi Environnement, while Vivendi Environnement will issue stock to investors that will further dilute Vivendi Universal’s shareholding to just above 40%, and raise up to 1.5 billion.
Editorial Office Elsevier Advanced Technology PO Box 150 Kidlington Oxford OX5 1AS United Kingdom Tel: +44 (0)1865 843676 Fax: +44 (0)1865 843971 E-mail: [email protected] Web: www.filtsep.com Editor Helen Long Permissions may be sought directly from Elsevier Science Rights & Permissions Department, PO Box 800, Oxford OX5 1DX, UK; phone: (+44) 1865 843830, fax: (+44) 1865 853333, e-mail: permissions @elsevier.co.uk. You may also contact Rights & Permissions directly through Elsevier’s home page (http://www.elsevier.nl), selecting first ‘Customer Support’, then ‘General Information’, then Permissions Query Form’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: (978) 7508400, fax: (978) 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: (+44) (0)20 7436 5931 ; fax: (+44) (0)20 7631 5500. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution. Permission of the publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Contact the publisher at the address indicated. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher. Address permissions requests to: Elsevier Science Rights & Permissions Department, at the mail, fax and e-mail addresses noted above. Notice No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
02207 Printed by Mayfield Press (Oxford) Limited, UK.
6/24/02
1:58 PM
Page 16
Filtration Industry Analyst
NEWS
CLARCOR ACQUIRES UK FILTER MAKER Clarcor Inc has acquired for around US$6.5 million Warrington-based Locker Filtration Ltd, a UK manufacturer of heavy-duty air filters, diesel and gas turbine air intake system filters and specialty filter products. The acquisition of Locker, with annual sales of around US$14.0 million, provides Clarcor with an air filter manufacturing facility in Europe, and will allow the company to provide its European sales organizations with an additional filter supply source. Currently, most of the air filter products sold by Clarcor into the European market are exported from the company’s North American plants. Norm Johnson, Clarcor’s chairman and CEO, said, “By transferring additional production into the Locker plant, we will be able to increase the utilization of its manufacturing capacity and improve the profitability of our European sales. In addition to lowering our European product acquisition costs, we will free up needed capacity in our North American manufacturing plants.”
H2O INNOVATION PURCHASES BIOTREATMENT COMPANIES H2O Innovation (2000) Inc has acquired the common and preferred shares of OxydH2O Canada Inc, Bioflo Inc and 3765415 Canada Inc (OxydH2O/Bioflo) for C$1.13 million. OxydH2O/Bioflo designs and manufactures turnkey systems for biological treatments using fixed film growths, such as the rotating biological reactor (RBR) and the textile Bioreactor Bio-Fosse, which uses a synthetic matrix as a biological support.
16
July 2002
“This acquisition is a tremendous business development opportunity for both organizations. The combination of our operations and technological know-how will immediately increase our sales and enhance the development of new market networks, since OxydH2O/Bioflo has representations in North Africa, Latin America, the Philippines and Canada,” said Guy Goulet, president and CEO of H2O Innovation. The purchase will extend H2O Innovation’s product line to include two products certified as standard by the Ministère de l’Environnement du Québec and the Ministère des Affaires Municipales et de la Métropole du Québec for wastewater treatment. It will also allow H2O Innovation to maximize production resources at its Ham-Nord plant in Quebec, and, says the company, to improve gross margins and break even more quickly. The C$1.13 million purchase price includes a cash payment of C$159 094, and C$289 105 payable by the issuance of 963 685 H2O Innovation common shares at the transaction’s closing date. Jean-Jacques Demers and Lise Nantel will continue to head OxydH2O/Bioflo.
OSMONICS TO INVEST IN NEW RO FACILITY Osmonics Inc is to build a dedicated, state-of-the-art reverse osmosis (RO) membrane and spiral-wound element factory in response to increased demand for its RO treatment technologies. The new factory will encompass a 60 000 square foot expansion of Osmonics’ existing Minnetonka headquarters and manufacturing facility, and increase the total size of the site by almost 20%. The new facility, complete with new manufacturing equipment,
is expected to be fully operational in 2004. “In addition to meeting future market demand, the expansion will allow us to incorporate new, more efficient manufacturing processes and equipment to streamline how we produce these high-volume products, resulting in faster time-to-market for our customers and higher returns for Osmonics,” said Dean Spatz, Osmonics’ CEO. The focused manufacturing plant will produce RO, nanofiltration and ultrafiltration membranes and elements for water purification applications. The extra space will also allow for expansion of current cartridge filtration production in the existing Minnetonka facility. Osmonics’ Filtration and Separations Group, which represents 40% of Osmonics’ total revenue, will be responsible for managing the extension project and eventual full-scale production.
VIVENDI PLANS WATER SELL-OFF Vivendi Universal’s board of directors and Vivendi Environnement’s supervisory board have approved a plan to raise up to 2 billion by reducing Vivendi Universal’s stake in Vivendi Environnement to just over 40% from around 63%. The move follows intense speculation that such a sale was likely, as the company continues making efforts to reduce its heavy debt load. The transaction will be completed when market conditions are appropriate and as soon as practicable. Vivendi Universal will sell around 15% of its shares in Vivendi Environnement, while Vivendi Environnement will issue stock to investors that will further dilute Vivendi Universal’s shareholding to just above 40%, and raise up to 1.5 billion.
Editorial Office Elsevier Advanced Technology PO Box 150 Kidlington Oxford OX5 1AS United Kingdom Tel: +44 (0)1865 843676 Fax: +44 (0)1865 843971 E-mail: [email protected] Web: www.filtsep.com Editor Helen Long Permissions may be sought directly from Elsevier Science Rights & Permissions Department, PO Box 800, Oxford OX5 1DX, UK; phone: (+44) 1865 843830, fax: (+44) 1865 853333, e-mail: permissions @elsevier.co.uk. You may also contact Rights & Permissions directly through Elsevier’s home page (http://www.elsevier.nl), selecting first ‘Customer Support’, then ‘General Information’, then Permissions Query Form’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: (978) 7508400, fax: (978) 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: (+44) (0)20 7436 5931 ; fax: (+44) (0)20 7631 5500. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution. Permission of the publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Contact the publisher at the address indicated. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher. Address permissions requests to: Elsevier Science Rights & Permissions Department, at the mail, fax and e-mail addresses noted above. Notice No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
02207 Printed by Mayfield Press (Oxford) Limited, UK.